Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study | Zendy

Christine Katlama | Zendy; Lambert Assoumou | Zendy; MarcAntoine Valantin | Zendy; Cathia Soulié | Zendy; Claudine Duvivier | Zendy; L. Chablais | Zendy; S. Kolta | Zendy; Gilles Pialoux | Zendy; P. Mercié | Zendy; Anne Simon | Zendy; Dominique Costagliola | Zendy; Gilles Peytavin | Zendy; AnneGeneviève Marcelin | Zendy; C. Katlama | Zendy; A. Simon | Zendy; Vincent Cálvez | Zendy; Jacqueline Capeau | Zendy; J.P. Bastard | Zendy; S. Couffin Cadiergues | Zendy; Juliette Saillard | Zendy; X. Rey-Coquais | Zendy; François Durand | Zendy; Claire A. Lemarchand | Zendy; Lise Cuzin | Zendy; J. P. Aboulker | Zendy; Harold Fisher | Zendy

Open Access

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study

Author(s) -

Christine Katlama,

Lambert Assoumou,

MarcAntoine Valantin,

Cathia Soulié,

Claudine Duvivier,

L. Chablais,

S. Kolta,

Gilles Pialoux,

P. Mercié,

Anne Simon,

Dominique Costagliola,

Gilles Peytavin,

AnneGeneviève Marcelin,

C. Katlama,

A. Simon,

Vincent Cálvez,

Jacqueline Capeau,

J.P. Bastard,

S. Couffin Cadiergues,

Juliette Saillard,

X. Rey-Coquais,

François Durand,

Claire A. Lemarchand,

Lise Cuzin,

J. P. Aboulker,

Harold Fisher

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkt536

Subject(s) - raltegravir , maraviroc , medicine , discontinuation , gastroenterology , adverse effect , viral load , integrase inhibitor , regimen , clinical endpoint , virology , randomized controlled trial , human immunodeficiency virus (hiv) , antiretroviral therapy

Novel nucleoside reverse transcriptase inhibitor- and protease inhibitor-sparing strategies are needed in long-term-treated patients with lipohypertrophy. Given their potency and their excellent metabolic profile, maraviroc and raltegravir appear to be good candidates for such an approach.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research